Trial Profile
A Phase 1b Placebo-controlled, Multi-centre, Randomized, Double-blind Dose Escalation Study to Evaluate the Pharmacokinetics (PK) and Safety of SMT C1100 in Patients With Duchenne Muscular Dystrophy (DMD) Who Follow a Balanced Diet
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ezutromid (Primary)
- Indications Duchenne muscular dystrophy
- Focus Pharmacokinetics
- Sponsors Summit Therapeutics
- 22 Jun 2017 According to a Summit Therapeutics media release, data from this trial will be presented at the European Paediatric Neurology Society Congress.
- 18 Dec 2015 Detailed results presented at the 20th World Muscle Society Congress, as per Summit Therapeutics media release.
- 30 Sep 2015 Results published in the Media Release